The global bariatric surgery devices market was valued at USD 2.10 billion in 2025. It is estimated at USD 2.18 billion in 2026 and is projected to reach USD 3.42 billion by 2036, growing at a CAGR of 4.6% over the 2026-2036 forecast period. This report provides a detailed assessment of the market, covering procedure volumes and mix, the effect of GLP-1 medications, technology developments, clinical evidence and guidelines, regulation and reimbursement, pricing, the value chain, and competition.
The study covers instruments, implants, and systems used in metabolic and bariatric procedures for obesity and related metabolic disease. Included are manual, powered, and robotic staplers with their reloads and staple-line reinforcement, energy devices for vessel sealing and dissection, trocars and liver retractors, suturing and closure tools, endoscopic devices used in endoscopic sleeve gastroplasty (ESG), intragastric balloons, adjustable bands, and robot-specific instruments. Procedures range from sleeve gastrectomy, Roux-en-Y gastric bypass, and one-anastomosis gastric bypass to duodenal switch and SADI-S, revisions, and endoscopic treatment. Robot capital systems and general instruments outside bariatric use are not counted.
According to the World Health Organization, 890 million adults were living with obesity in 2022, and the ASMBS reported that under 1% of eligible patients undergo an operation in any year, leaving a large and mostly untreated patient pool. At the same time, GLP-1 drugs have reduced surgical demand; according to American College of Surgeons figures shared at the ASMBS meeting in May 2026, procedures at accredited American centers dropped to just over 177,000 in 2024, 23% below the 2022 peak of more than 230,000. Surgery still delivers far greater weight loss, as a 51,085-patient study by NYU Langone Health and NYC Health + Hospitals reported 24% total weight loss after two years with surgery against 4.7% with semaglutide or tirzepatide.
Substitution by GLP-1 medications is the main restraint, as bariatric cases in the Epic Cosmos database fell from 42,615 in 2023 to 33,429 in 2025 while GLP-1 prescriptions rose above 1.42 million, and Intuitive Surgical reported that its U.S. bariatric da Vinci cases fell at high single-digit rates for six quarters in a row. Prior authorization rules, supervised weight-loss requirements, public waiting lists, and high out-of-pocket costs limit access, and fear of complications and stigma deter many patients. Demand for intragastric balloons and gastric bands has also dropped sharply; according to ASMBS estimates, U.S. balloon procedures fell from 4,358 in 2022 to 1,461 in 2023. Challenges include forecasting volumes, building care pathways that combine drugs and surgery, adjusting portfolios to a changing procedure mix, and proving the value of endoscopic treatment.
Revisional surgery is a key opportunity, as some sleeve patients face weight regain or reflux and need conversion, often using more reloads, reinforcement, and energy devices per case. Endoscopic therapy is a second opportunity, supported by the FDA's July 2022 ESG indication for Apollo Endosurgery's suturing system, Boston Scientific's 2023 purchase of Apollo, and the MERIT trial in The Lancet, which reported 13.6% total weight loss with ESG at 52 weeks. Rising case numbers in emerging regions where GLP-1 drugs remain costly add further potential. Key trends include the move from sleeve gastrectomy to gastric bypass, drug and surgery pathways used together, rising robotic surgery, and maturing endoscopic therapy; according to American College of Surgeons data, sleeve gastrectomy slipped from 64% to 58% of American procedures between 2020 and 2024, while gastric bypass climbed from 28% to 33%.
By product, the study covers stapling devices (manual staplers, powered staplers, and reloads & staple-line reinforcement), energy devices, access devices (trocars and retractors), suturing devices, endoscopic bariatric devices, intragastric balloons, gastric bands, and robotic instruments & accessories. Stapling devices are expected to lead in 2026, because every sleeve, bypass, and revision consumes several reloads, many surgeons add staple-line reinforcement, and powered and robotic staplers carry higher prices. Endoscopic bariatric devices are set to post the highest CAGR, helped by the FDA's dedicated ESG indication, trial results such as MERIT, and patient demand for treatment that avoids surgery. Balloons and bands are expected to remain under pressure as medication offers a non-surgical alternative for similar patients.
The procedure analysis spans sleeve gastrectomy, Roux-en-Y gastric bypass, duodenal switch & SADI-S, one-anastomosis gastric bypass, revisional surgery, endoscopic procedures (endoscopic sleeve gastroplasty and intragastric balloon placement), and adjustable gastric banding. Sleeve gastrectomy is expected to lead in 2026, as it remains the most common bariatric operation thanks to its technical simplicity and low early complication rate. Revisional surgery is set to grow the fastest, as earlier sleeve patients are converted to bypass for reflux or weight regain and these complex cases use more devices. Gastric bypass is also gaining ground as surgeons reassess procedure selection.
By approach, the report examines laparoscopic, robotic-assisted, endoscopic, and open surgery. Laparoscopic surgery is expected to lead in 2026, as it is the standard method for primary bariatric operations across the world and is supported by a large base of trained surgeons and established stapling and access products. Robotic-assisted surgery is set to record the highest CAGR, as the shift toward bypass and revisions favors articulated instruments and robotic staplers, and new robotic systems from Medtronic, Johnson & Johnson, and others enter the market. Endoscopic approaches add a less invasive option for moderate obesity.
Among end users, which include hospitals, ambulatory surgery centers, and specialty bariatric centers, hospitals are expected to lead in 2026, as they house most accredited bariatric programs, provide inpatient beds and critical care backup, and handle complex and revisional cases. Ambulatory surgery centers are set to grow the fastest, supported by more outpatient sleeve gastrectomy and endoscopic procedures and by payer and provider efforts to lower the cost of each case. Specialty bariatric centers remain important for high-volume programs and medical tourism.
North America is expected to hold the largest share in 2026, as the U.S. performs more bariatric procedures than any other country, has dense networks of accredited centers, and makes heavy use of advanced stapling and robotic systems; according to the ASMBS, 270,089 procedures were performed in the U.S. in 2023. Medicare has covered eligible patients since 2006, and leading suppliers such as Medtronic, Johnson & Johnson MedTech, Intuitive Surgical, and Boston Scientific are active in the market, though the region also feels the strongest GLP-1 effect. Europe holds a significant share, as public health services across the region's major countries and the Nordics fund surgery, many do not reimburse GLP-1 drugs for weight loss, and European surgeons helped develop one-anastomosis bypass and SADI-S.
Asia-Pacific is set to grow at the highest CAGR, driven by large populations with obesity and type 2 diabetes, the lower BMI threshold for Asian patients, more bariatric centers and local stapler makers in China, growing private hospital programs in India, and high GLP-1 costs relative to income. Latin America also holds a significant share, led by Brazil, where both private insurance and the public Unified Health System cover surgery, and Mexico, which also serves U.S. medical tourists, with Colombia, Argentina, and Chile adding centers. The Middle East & Africa is expected to grow strongly, as Kuwait, Saudi Arabia, Qatar, and the UAE combine very high obesity rates with high-volume programs, and Türkiye serves as a bariatric tourism hub.
The market is moderately consolidated, as a few large device companies lead stapling and energy, robotic surgery firms supply robotic staplers and instruments, endoscopy companies offer endoscopic systems, and smaller firms focus on balloons, bands, and bariatric-specific tools. Suppliers compete on secure staple lines, powered and smart staplers, fit with robotic platforms, outcomes data, training support, and contract pricing with hospitals and GPOs. Leaders are putting money into next-generation staplers, reinforcement materials, endoscopic suturing, and surgeon education while adjusting portfolios to lower volumes and more bypass and revision work; Boston Scientific's 2023 purchase of Apollo Endosurgery shows consolidation in endoscopic therapy.
Key companies profiled in the report include Medtronic plc (Ireland), Johnson & Johnson MedTech (Ethicon) (U.S.), Intuitive Surgical, Inc. (U.S.), Teleflex Incorporated (U.S.), CONMED Corporation (U.S.), Applied Medical Resources Corporation (U.S.), B. Braun Melsungen AG (Germany), KARL STORZ SE & Co. KG (Germany), Boston Scientific Corporation (U.S.), Olympus Corporation (Japan), Cook Medical LLC (U.S.), Allurion Technologies, Inc. (U.S.), ReShape Lifesciences Inc. (U.S.), Spatz Medical (U.S.), Reach Surgical, Inc. (China), and Fengh Medical Co., Ltd. (China).
The study covers instruments, implants, and systems used in metabolic and bariatric procedures for obesity and related metabolic disease. Included are manual, powered, and robotic staplers with their reloads and staple-line reinforcement, energy devices for vessel sealing and dissection, trocars and liver retractors, suturing and closure tools, endoscopic devices used in endoscopic sleeve gastroplasty (ESG), intragastric balloons, adjustable bands, and robot-specific instruments. Procedures range from sleeve gastrectomy, Roux-en-Y gastric bypass, and one-anastomosis gastric bypass to duodenal switch and SADI-S, revisions, and endoscopic treatment. Robot capital systems and general instruments outside bariatric use are not counted.
According to the World Health Organization, 890 million adults were living with obesity in 2022, and the ASMBS reported that under 1% of eligible patients undergo an operation in any year, leaving a large and mostly untreated patient pool. At the same time, GLP-1 drugs have reduced surgical demand; according to American College of Surgeons figures shared at the ASMBS meeting in May 2026, procedures at accredited American centers dropped to just over 177,000 in 2024, 23% below the 2022 peak of more than 230,000. Surgery still delivers far greater weight loss, as a 51,085-patient study by NYU Langone Health and NYC Health + Hospitals reported 24% total weight loss after two years with surgery against 4.7% with semaglutide or tirzepatide.
Market Dynamics
Demand for bariatric devices rests first on the scale of untreated severe obesity: an analysis of health records for nearly 20 million U.S. patients, presented at the ASMBS 2026 meeting, reported that 90% to 95% received no obesity treatment between 2018 and 2025. The second factor is the lasting weight loss surgery achieves, while NYU Langone researchers reported that as many as 70% of patients may stop GLP-1 therapy within a year. The third factor is wider eligibility, as the 2022 ASMBS and IFSO guidelines recommend surgery at a BMI of 35 or higher regardless of comorbidities, suggest it at a BMI of 30 to 34.9 with metabolic disease, lower the threshold to 27.5 for Asian patients, and support use in selected adolescents.Substitution by GLP-1 medications is the main restraint, as bariatric cases in the Epic Cosmos database fell from 42,615 in 2023 to 33,429 in 2025 while GLP-1 prescriptions rose above 1.42 million, and Intuitive Surgical reported that its U.S. bariatric da Vinci cases fell at high single-digit rates for six quarters in a row. Prior authorization rules, supervised weight-loss requirements, public waiting lists, and high out-of-pocket costs limit access, and fear of complications and stigma deter many patients. Demand for intragastric balloons and gastric bands has also dropped sharply; according to ASMBS estimates, U.S. balloon procedures fell from 4,358 in 2022 to 1,461 in 2023. Challenges include forecasting volumes, building care pathways that combine drugs and surgery, adjusting portfolios to a changing procedure mix, and proving the value of endoscopic treatment.
Revisional surgery is a key opportunity, as some sleeve patients face weight regain or reflux and need conversion, often using more reloads, reinforcement, and energy devices per case. Endoscopic therapy is a second opportunity, supported by the FDA's July 2022 ESG indication for Apollo Endosurgery's suturing system, Boston Scientific's 2023 purchase of Apollo, and the MERIT trial in The Lancet, which reported 13.6% total weight loss with ESG at 52 weeks. Rising case numbers in emerging regions where GLP-1 drugs remain costly add further potential. Key trends include the move from sleeve gastrectomy to gastric bypass, drug and surgery pathways used together, rising robotic surgery, and maturing endoscopic therapy; according to American College of Surgeons data, sleeve gastrectomy slipped from 64% to 58% of American procedures between 2020 and 2024, while gastric bypass climbed from 28% to 33%.
Segment Analysis
The report analyzes the market by product, procedure, approach, end user, and geography, helping stakeholders identify where device value is concentrated and where demand is shifting.By product, the study covers stapling devices (manual staplers, powered staplers, and reloads & staple-line reinforcement), energy devices, access devices (trocars and retractors), suturing devices, endoscopic bariatric devices, intragastric balloons, gastric bands, and robotic instruments & accessories. Stapling devices are expected to lead in 2026, because every sleeve, bypass, and revision consumes several reloads, many surgeons add staple-line reinforcement, and powered and robotic staplers carry higher prices. Endoscopic bariatric devices are set to post the highest CAGR, helped by the FDA's dedicated ESG indication, trial results such as MERIT, and patient demand for treatment that avoids surgery. Balloons and bands are expected to remain under pressure as medication offers a non-surgical alternative for similar patients.
The procedure analysis spans sleeve gastrectomy, Roux-en-Y gastric bypass, duodenal switch & SADI-S, one-anastomosis gastric bypass, revisional surgery, endoscopic procedures (endoscopic sleeve gastroplasty and intragastric balloon placement), and adjustable gastric banding. Sleeve gastrectomy is expected to lead in 2026, as it remains the most common bariatric operation thanks to its technical simplicity and low early complication rate. Revisional surgery is set to grow the fastest, as earlier sleeve patients are converted to bypass for reflux or weight regain and these complex cases use more devices. Gastric bypass is also gaining ground as surgeons reassess procedure selection.
By approach, the report examines laparoscopic, robotic-assisted, endoscopic, and open surgery. Laparoscopic surgery is expected to lead in 2026, as it is the standard method for primary bariatric operations across the world and is supported by a large base of trained surgeons and established stapling and access products. Robotic-assisted surgery is set to record the highest CAGR, as the shift toward bypass and revisions favors articulated instruments and robotic staplers, and new robotic systems from Medtronic, Johnson & Johnson, and others enter the market. Endoscopic approaches add a less invasive option for moderate obesity.
Among end users, which include hospitals, ambulatory surgery centers, and specialty bariatric centers, hospitals are expected to lead in 2026, as they house most accredited bariatric programs, provide inpatient beds and critical care backup, and handle complex and revisional cases. Ambulatory surgery centers are set to grow the fastest, supported by more outpatient sleeve gastrectomy and endoscopic procedures and by payer and provider efforts to lower the cost of each case. Specialty bariatric centers remain important for high-volume programs and medical tourism.
Regional Analysis
The report covers North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa, with analysis of 22 countries, the Nordic countries, Southeast Asia, UAE & Qatar, and five rest-of-region groups. The analysis considers obesity prevalence, procedure volumes, eligibility rules, reimbursement, GLP-1 affordability, and surgical capacity.North America is expected to hold the largest share in 2026, as the U.S. performs more bariatric procedures than any other country, has dense networks of accredited centers, and makes heavy use of advanced stapling and robotic systems; according to the ASMBS, 270,089 procedures were performed in the U.S. in 2023. Medicare has covered eligible patients since 2006, and leading suppliers such as Medtronic, Johnson & Johnson MedTech, Intuitive Surgical, and Boston Scientific are active in the market, though the region also feels the strongest GLP-1 effect. Europe holds a significant share, as public health services across the region's major countries and the Nordics fund surgery, many do not reimburse GLP-1 drugs for weight loss, and European surgeons helped develop one-anastomosis bypass and SADI-S.
Asia-Pacific is set to grow at the highest CAGR, driven by large populations with obesity and type 2 diabetes, the lower BMI threshold for Asian patients, more bariatric centers and local stapler makers in China, growing private hospital programs in India, and high GLP-1 costs relative to income. Latin America also holds a significant share, led by Brazil, where both private insurance and the public Unified Health System cover surgery, and Mexico, which also serves U.S. medical tourists, with Colombia, Argentina, and Chile adding centers. The Middle East & Africa is expected to grow strongly, as Kuwait, Saudi Arabia, Qatar, and the UAE combine very high obesity rates with high-volume programs, and Türkiye serves as a bariatric tourism hub.
Competitive Landscape
The report reviews key growth strategies, competitive benchmarking, and the competitive dashboard, which groups companies into industry leaders, market differentiators, vanguards, and emerging companies, along with a 2025 market share/rank analysis. Company profiles, grouped into stapling, energy, and robotics leaders, endoscopic and less-invasive device companies, and Asia-Pacific manufacturers, cover business overview, financials, product portfolio, strategic developments, and SWOT analysis.The market is moderately consolidated, as a few large device companies lead stapling and energy, robotic surgery firms supply robotic staplers and instruments, endoscopy companies offer endoscopic systems, and smaller firms focus on balloons, bands, and bariatric-specific tools. Suppliers compete on secure staple lines, powered and smart staplers, fit with robotic platforms, outcomes data, training support, and contract pricing with hospitals and GPOs. Leaders are putting money into next-generation staplers, reinforcement materials, endoscopic suturing, and surgeon education while adjusting portfolios to lower volumes and more bypass and revision work; Boston Scientific's 2023 purchase of Apollo Endosurgery shows consolidation in endoscopic therapy.
Key companies profiled in the report include Medtronic plc (Ireland), Johnson & Johnson MedTech (Ethicon) (U.S.), Intuitive Surgical, Inc. (U.S.), Teleflex Incorporated (U.S.), CONMED Corporation (U.S.), Applied Medical Resources Corporation (U.S.), B. Braun Melsungen AG (Germany), KARL STORZ SE & Co. KG (Germany), Boston Scientific Corporation (U.S.), Olympus Corporation (Japan), Cook Medical LLC (U.S.), Allurion Technologies, Inc. (U.S.), ReShape Lifesciences Inc. (U.S.), Spatz Medical (U.S.), Reach Surgical, Inc. (China), and Fengh Medical Co., Ltd. (China).
How This Report Helps
- Provides reliable market size estimates and long-term forecasts for the global bariatric surgery devices market through 2036.
- Explains how GLP-1 medications are changing procedure volumes, the procedure mix, and patient pathways.
- Assesses the effect of access barriers, patient concerns, and falling balloon and band demand on device revenue.
- Identifies high-growth opportunities across product, procedure, approach, end user, and region.
- Tracks technology and evidence trends in powered and robotic staplers, reinforcement materials, and endoscopic suturing.
- Benchmarks stapling, robotics, endoscopy, and specialist bariatric device companies on portfolios and strategies.
- Supports product planning, pricing, market entry, and investment decisions for device makers, hospitals, and investors.
Key Questions Answered
- How large is the global bariatric surgery devices market today, and how fast will it grow through 2036?
- How much have GLP-1 medications reduced bariatric procedure volumes, and when could volumes stabilize?
- What are the main drivers, restraints, opportunities, challenges, and trends shaping the market?
- How is the shift from sleeve gastrectomy to gastric bypass and revisional surgery changing device use per case?
- Which product, procedure, approach, and end user segments will grow the fastest?
- How quickly will endoscopic sleeve gastroplasty and robotic-assisted bariatric surgery be adopted?
- Which regions and countries offer the most attractive opportunities as growth shifts outside the U.S.?
- Who are the leading companies in the market, and how do they compare?
- What acquisitions, product developments, and evidence programs are shaping competition?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Bariatric Surgery Devices Market, by Product
6. Bariatric Surgery Devices Market, by Procedure
7. Bariatric Surgery Devices Market, by Approach
8. Bariatric Surgery Devices Market, by End User
9. Bariatric Surgery Devices Market, by Geography
10. Competitive Landscape
11. Company Profiles
12. Appendix
LIST OF TABLES
LIST OF FIGURES
Companies Mentioned
- Medtronic plc
- Johnson & Johnson MedTech
- Intuitive Surgical, Inc.
- Teleflex Incorporated
- CONMED Corporation
- Applied Medical Resources Corporation
- B. Braun Melsungen AG
- KARL STORZ SE & Co. KG
- Boston Scientific Corporation
- Olympus Corporation
- Cook Medical LLC
- Allurion Technologies, Inc.
- ReShape Lifesciences Inc.
- Spatz Medical
- Reach Surgical, Inc.
- Fengh Medical Co., Ltd.
